[go: up one dir, main page]

FR3039166B1 - Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes - Google Patents

Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes Download PDF

Info

Publication number
FR3039166B1
FR3039166B1 FR1557020A FR1557020A FR3039166B1 FR 3039166 B1 FR3039166 B1 FR 3039166B1 FR 1557020 A FR1557020 A FR 1557020A FR 1557020 A FR1557020 A FR 1557020A FR 3039166 B1 FR3039166 B1 FR 3039166B1
Authority
FR
France
Prior art keywords
proplaquets
cd41dim
carriing
megacaryocyte
plaquettes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1557020A
Other languages
English (en)
Other versions
FR3039166A1 (fr
Inventor
Catherine STRASSEL
Christian Gachet
Francois Lanza
Nathalie BROUARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Etablissement Francais du Sang
Universite de Strasbourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1557020A priority Critical patent/FR3039166B1/fr
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Etablissement Francais du Sang, Universite de Strasbourg filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to CN201680047758.8A priority patent/CN107922924B/zh
Priority to EP16742302.9A priority patent/EP3334822B1/fr
Priority to AU2016296920A priority patent/AU2016296920B2/en
Priority to US15/747,023 priority patent/US11236303B2/en
Priority to PCT/EP2016/067594 priority patent/WO2017013262A1/fr
Priority to JP2018503184A priority patent/JP7068162B6/ja
Priority to CA2993596A priority patent/CA2993596A1/fr
Publication of FR3039166A1 publication Critical patent/FR3039166A1/fr
Application granted granted Critical
Publication of FR3039166B1 publication Critical patent/FR3039166B1/fr
Priority to JP2021121618A priority patent/JP2021177774A/ja
Priority to US17/547,444 priority patent/US20220135946A1/en
Priority to US18/820,807 priority patent/US20240417686A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2309—Interleukin-9 (IL-9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR1557020A 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes Active FR3039166B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR1557020A FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
CA2993596A CA2993596A1 (fr) 2015-07-23 2016-07-22 Cellules progenitrices de megacaryocytes cd34+cd41dim et utilisations associees pour la production de megacaryocytes et/ou de plaquettes portant des proplaquettes
AU2016296920A AU2016296920B2 (en) 2015-07-23 2016-07-22 CD34+CD41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
US15/747,023 US11236303B2 (en) 2015-07-23 2016-07-22 CD34+CD41DIM megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
PCT/EP2016/067594 WO2017013262A1 (fr) 2015-07-23 2016-07-22 Cellules progénitrices de mégacaryocytes cd34+cd41dim et utilisations associées pour la production de mégacaryocytes et/ou de plaquettes portant des proplaquettes
JP2018503184A JP7068162B6 (ja) 2015-07-23 2016-07-22 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。
CN201680047758.8A CN107922924B (zh) 2015-07-23 2016-07-22 巨核细胞祖细胞及其产生带有前血小板的mk和/或血小板的应用
EP16742302.9A EP3334822B1 (fr) 2015-07-23 2016-07-22 Cellules progénitrices de mégacaryocytes cd34+cd41dim et utilisations associées pour la production de mégacaryocytes et/ou de plaquettes portant des proplaquettes
JP2021121618A JP2021177774A (ja) 2015-07-23 2021-07-26 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。
US17/547,444 US20220135946A1 (en) 2015-07-23 2021-12-10 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets
US18/820,807 US20240417686A1 (en) 2015-07-23 2024-08-30 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1557020 2015-07-23
FR1557020A FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Publications (2)

Publication Number Publication Date
FR3039166A1 FR3039166A1 (fr) 2017-01-27
FR3039166B1 true FR3039166B1 (fr) 2018-10-26

Family

ID=55072774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1557020A Active FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Country Status (8)

Country Link
US (3) US11236303B2 (fr)
EP (1) EP3334822B1 (fr)
JP (2) JP7068162B6 (fr)
CN (1) CN107922924B (fr)
AU (1) AU2016296920B2 (fr)
CA (1) CA2993596A1 (fr)
FR (1) FR3039166B1 (fr)
WO (1) WO2017013262A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3039166B1 (fr) * 2015-07-23 2018-10-26 Institut National De La Sante Et De La Recherche Medicale Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
WO2020006539A1 (fr) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions pour l'administration de médicaments et leurs méthodes d'utilisation
FR3101885B1 (fr) 2019-10-11 2024-11-08 Francais Du Sang Ets Systeme pour la liberation de plaquettes et procede de liberation de plaquettes
CN115868454B (zh) * 2022-12-23 2025-09-02 中国医学科学院血液病医院(中国医学科学院血液学研究所) 基于免疫缺陷小鼠移植检测人巨核偏向造血干细胞功能方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024875A2 (fr) * 2002-09-13 2004-03-25 The Board Of Trustees Of The Leland Stanford Junior University Cellule souche mammifere de megakaryocytes
WO2009119105A1 (fr) 2008-03-28 2009-10-01 国立大学法人東京大学 PROCÉDÉ DE PRÉPARATION IN VITRO DE PLAQUETTE GPIBα+GPV+GPVI+
WO2012129109A2 (fr) 2011-03-18 2012-09-27 New York Blood Center, Inc. Production de mégacaryocytes et de plaquettes à partir de cellules souches
US9920295B2 (en) 2012-02-21 2018-03-20 The Trustees Of The University Of Pennsylvania Bioreactor for isolation of rare cells and methods of use
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
GB201220937D0 (en) * 2012-11-21 2013-01-02 Airbus Uk Ltd Modular structural assembly
WO2014138485A1 (fr) * 2013-03-08 2014-09-12 Irm Llc Production de plaquettes ex vivo à partir de cellules souches hématopoïétiques et leur produit
FR3039166B1 (fr) * 2015-07-23 2018-10-26 Institut National De La Sante Et De La Recherche Medicale Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Also Published As

Publication number Publication date
JP2018519845A (ja) 2018-07-26
CA2993596A1 (fr) 2017-01-26
EP3334822A1 (fr) 2018-06-20
US20240417686A1 (en) 2024-12-19
EP3334822B1 (fr) 2025-10-15
US20180216068A1 (en) 2018-08-02
US11236303B2 (en) 2022-02-01
JP2021177774A (ja) 2021-11-18
JP7068162B2 (ja) 2022-05-16
AU2016296920A1 (en) 2018-02-15
WO2017013262A1 (fr) 2017-01-26
CN107922924A (zh) 2018-04-17
US20220135946A1 (en) 2022-05-05
FR3039166A1 (fr) 2017-01-27
CN107922924B (zh) 2022-01-11
AU2016296920B2 (en) 2022-05-26
JP7068162B6 (ja) 2023-12-20

Similar Documents

Publication Publication Date Title
FR25C1020I1 (fr) Anticorps thérapeutiques et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
EP3389658A4 (fr) Inhibiteurs de glycosidase et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3337470A4 (fr) Conjugués d'aldéhyde et leurs utilisations
MA53400A (fr) Hétéromultimères alk7: actriib et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3334706A4 (fr) Pillararènes et utilisations de ceux-ci
EP3328895A4 (fr) Anticorps anti-pd-l1 et leurs utilisations
MA46472A (fr) Hétéromultimères alk4:actriib et leurs utilisations
EP3413816A4 (fr) Compositions hydratantes et utilisations associées
EP3344624A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
MA55044A (fr) Hétéromultimères alk4:actriib et leurs utilisations
MA44262A (fr) Bioconjugués et utilisations de ceux-ci
EP3364958A4 (fr) Modulateurs d'interaction sestrine-gator2 et leurs utilisations
EP3370528A4 (fr) Compositions probiotiques et leurs utilisations
EP3341387A4 (fr) Inhibiteurs de sialyltransférase et utilisations de ceux-ci
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3329400A4 (fr) Désambiguïsation des interrogations de recherche
EP2968107A4 (fr) Compositions cosmétiques et leurs utilisations
EP3347021A4 (fr) Cyano-thiénotriazoloazépines et leurs utilisations
EP3638251A4 (fr) Formulations de gel de bisphosphocine et leurs utilisations
FR3018191B1 (fr) Utilisations cosmetiques de la swertiamarine

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

EXTE Extension to a french territory

Extension state: PF

PLSC Publication of the preliminary search report

Effective date: 20170127

PLFP Fee payment

Year of fee payment: 3

TQ Partial transmission of property

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20180319

Owner name: UNIVERSITE DE STRASBOURG, FR

Effective date: 20180319

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11